Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.070-0.110 for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $863.0 million.

Myriad Genetics Price Performance

Shares of NASDAQ:MYGN traded down $0.34 during midday trading on Friday, hitting $10.18. The company had a trading volume of 819,577 shares, compared to its average volume of 1,155,522. The business's 50-day simple moving average is $13.02 and its 200-day simple moving average is $18.55. The stock has a market cap of $929.53 million, a price-to-earnings ratio of -7.83 and a beta of 1.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics has a twelve month low of $9.76 and a twelve month high of $29.30.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). The company had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period last year, the business earned ($0.12) earnings per share. On average, research analysts predict that Myriad Genetics will post -0.3 earnings per share for the current year.

Remove Ads

Analysts Set New Price Targets

Several research firms have weighed in on MYGN. UBS Group decreased their target price on shares of Myriad Genetics from $18.00 to $16.00 and set a "neutral" rating on the stock in a report on Tuesday, February 25th. Leerink Partners cut Myriad Genetics from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $30.00 to $21.00 in a report on Monday, December 9th. Piper Sandler cut their target price on Myriad Genetics from $14.00 to $11.50 and set a "neutral" rating for the company in a research note on Tuesday. Craig Hallum began coverage on Myriad Genetics in a research note on Wednesday, February 12th. They issued a "buy" rating and a $29.00 price target on the stock. Finally, StockNews.com cut Myriad Genetics from a "buy" rating to a "hold" rating in a report on Saturday, March 1st. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Myriad Genetics has a consensus rating of "Hold" and a consensus price target of $21.82.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.